Earlier this month, the FDA slapped down Pfizer's Xeljanz as a treatment for moderate to severe cases of plaque psoriasis. And that could be the end of the line for the med in that indication, execs said Tuesday.
After a strong first half, Pfizer's vaccine unit didn't let up in the third quarter, continuing on an upward trajectory as growing Prevnar 13 sales continued to propel the unit forward.
On the company's third-quarter earnings call, Pfizer Chairman and CEO Ian Read fended off repeated questions on a new structure for the company that could be spurred by tax changes while letting a key executive paint a broad picture of how cash stashed abroad may play a part in any decision.
Last quarter, vaccine giant Prevnar 13 and breast-cancer newcomer Ibrance outperformed expectations, helping Pfizer trump analyst estimates. And in Q3, they delivered repeat performances.
Pfizer, deepening its efforts in biosimilars after trading $17 billion for Hospira, is ditching a few redundant assets partnered with South Korean drugmaker Celltrion, paring down its pipeline as it eyes a growing global market.
Pfizer is enlisting the power of pictures for its next chapter in its metastatic breast cancer awareness campaign. For "Story Half Told," the pharma has hired 5 prominent Instagram photographers to chronicle the everyday lives of women living with MBC.
Pfizer has found new hope for a former pipeline standout, picking up the FDA's coveted breakthrough therapy designation for a Phase III reclamation project in oncology.
Tracy Staton wrote an article on Thursday, based on a piece in Forbes. Pfizer took exception to our article and sent a statement.
Pfizer will have to keep waiting on its hopes for Xeljanz (tofacitinib) expansion. For now, the FDA has turned down the slow-starting med as a treatment for moderate to severe cases of plaque psoriasis.
Pfizer CEO Ian Read says he's met the drug-cost enemy, and it isn't pharma. The firestorm over U.S. drug pricing isn't a problem for drugmakers to solve, Read told Forbes in an interview. It's an insurance problem.